Wechselwirkungen · Descovy
Descovy 200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-134971 · Präparat HOS-097638
Rilpivirine: AUC: ↔ Cmax: ↔ Cmin: ↔ Efavirenz (600 mg once daily), Tenofovir alafenamide: The recommended dose of Descovy tenofovir alafenamide (40 mg AUC: ↓ 14% is 200/25 mg once daily. once daily)4 Cmax: ↓ 22% Maraviroc Interaction not studied with either of The recommended dose of Descovy Nevirapine the components of Descovy. is 200/25 mg once daily. Raltegravir Tenofovir alafenamide exposure is not expected to be affected by maraviroc, nevirapine or raltegravir, nor is it expected to affect the metabolic and excretion pathways relevant to maraviroc, nevirapine or raltegravir. ANTICONVULSANTS Oxcarbazepine Interaction not studied with either of Co-administration of Descovy and Phenobarbital the components of Descovy. oxcarbazepine, phenobarbital or Phenytoin phenytoin is not recommended. Co-administration of oxcarbazepine, phenobarbital, or phenytoin, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. Carbamazepine (titrated from Tenofovir alafenamide: Co-administration of Descovy and 100 mg to 300 mg twice a day), AUC: ↓ 55% carbamazepine is not emtricitabine/tenofovir Cmax: ↓ 57% recommended. alafenamide (200 mg/25 mg once daily) 5,6 Co-administration of carbamazepine, a P-gp inducer, decreases tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) phenobarbital (HOS-085617) carbamazepine (HOS-085618) maraviroc (HOS-086186) rilpivirine (HOS-088090) efavirenz (HOS-087947) raltegravir (HOS-086187) nevirapine (HOS-088064) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage b71365c2f5767995bea9e5e1815428c4354bf239dd82b6bda3e197293a3eba4c · Zeichen 16467–19106 im Abschnitt